Abstract T P157: The Impact of Estimated Glomerular Filtration Rate on a Recurrence of Ischemic Stroke: The Fukuoka Stroke Registry
Introduction: Although chronic kidney disease has been shown as a risk factor for stroke recurrence in several studies, there are few reports about the impact of the degree of estimated glomerular filtration rate (eGFR) on recurrence.
Hypothesis: There is a trend that hazard ratio of stroke recurrence was lower in the higher group of eGFR while higher in the lower group. We aimed to determine the influence of eGFR grade on stroke recurrence.
Methods: We enrolled 5101 consecutive patients who were hospitalized in stroke centers within seven days of onset from June 2007 to May 2012. The clinical characteristics of patients were assessed on admission, and the clinical course of all patients was followed subsequently. Patients were divided into three groups based on the level of eGFR; E1 (eGFR < 30 ml/min/1.73 m2), E2 (30 ≤ eGFR < 60), E3 (60 ≤ eGFR). In these groups, we performed Multivariate Cox proportional hazards analyses to determine the influence of eGFR grade on stroke recurrence.
Results: Of all patients, 5028 (2998 males, 74 ± 12 years of age) cases with ischemic stroke were investigated in the present study. Six hundred twenty-nine patients (13%) suffered a recurrence of ischemic stroke during the follow-up period (680 ± 387 days). The Kaplan-Meier method revealed the cumulative recurrence rates of ischemic stroke in three groups of patients were significantly different, as shown in figure (E1 vs. E2, E1 vs. E3, p < 0.0001 by the log-rank test). On Cox proportional analysis with adjustments for multiple confounding factors, E2 (hazard ratio [HR] 1.27, 95% confidence interval [CI] 1.06 to 1.52, p = 0.0115) and E3 ([HR] 1.95, 95% [CI] 1.48 to 2.52, p < 0.0001) groups were at greater risk of stroke recurrence compared with the E1 group.
Conclusions: There is the significant relationship between a level of eGFR and a recurrence of ischemic stroke. In the stroke patients who have lower eGFR, the risk of a recurrence more increases.
Author Disclosures: T. Kuwashiro: None. M. Kamouchi: None. Y. Kumai: None. K. Maeda: None. T. Uwatoko: None. Y. Wakugawa: None. T. Ago: None. M. Yasaka: None. Y. Okada: None. T. Kitazono: None.
- © 2014 by American Heart Association, Inc.